Aaron Wealth Advisors LLC Grows Stock Position in MBX Biosciences, Inc. $MBX

Aaron Wealth Advisors LLC boosted its stake in shares of MBX Biosciences, Inc. (NASDAQ:MBX) by 40.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 70,000 shares of the company’s stock after buying an additional 20,000 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in MBX Biosciences were worth $2,208,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of MBX. Russell Investments Group Ltd. raised its holdings in MBX Biosciences by 4,131.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after buying an additional 1,446 shares during the period. FNY Investment Advisers LLC purchased a new stake in MBX Biosciences during the 3rd quarter valued at $27,000. BNP Paribas Financial Markets raised its holdings in MBX Biosciences by 117.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock valued at $51,000 after buying an additional 1,567 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in MBX Biosciences during the 3rd quarter valued at $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in MBX Biosciences by 40.3% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,329 shares of the company’s stock valued at $106,000 after buying an additional 2,682 shares during the period.

Insider Activity

In other news, CEO P. Kent Hawryluk purchased 18,500 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were acquired at an average price of $28.41 per share, with a total value of $525,585.00. Following the transaction, the chief executive officer owned 486,777 shares of the company’s stock, valued at $13,829,334.57. This represents a 3.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 52.19% of the company’s stock.

MBX Biosciences Stock Down 5.1%

Shares of MBX Biosciences stock opened at $31.30 on Tuesday. The stock’s fifty day moving average is $33.20 and its two-hundred day moving average is $28.68. The company has a market capitalization of $1.49 billion, a PE ratio of -12.99 and a beta of 1.25. MBX Biosciences, Inc. has a 52 week low of $4.81 and a 52 week high of $44.89.

MBX Biosciences (NASDAQ:MBX) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.15.

Analysts Set New Price Targets

Several research firms recently weighed in on MBX. Guggenheim increased their price target on MBX Biosciences from $77.00 to $88.00 and gave the company a “buy” rating in a report on Friday, January 16th. Lifesci Capital upgraded MBX Biosciences to a “strong-buy” rating in a report on Tuesday, March 31st. TD Cowen restated a “buy” rating on shares of MBX Biosciences in a report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MBX Biosciences in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised MBX Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, December 21st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $51.56.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.